Servier Unveils Key Data at ASCO 2026 with Focus on Rare Oncology Innovations

Servier's Important Presentations at ASCO 2026

Servier Pharmaceuticals is set to make a notable presence at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place from May 29 to June 2 in Chicago. The company will showcase both new and updated findings, emphasizing its ongoing commitment to addressing the needs of patients suffering from rare forms of cancer.

Significant Presentations Planned

As part of this year's highlights, Servier will present critical data from its long-term analysis of the Phase 3 INDIGO trial examining VORANIGO® (vorasidenib). The results of this trial will provide essential insights into the efficacy and safety of this treatment for patients with Grade 2 IDH-mutant glioma. A rapid oral presentation on May 31 at 4:36 p.m. CDT is anticipated to stir interest, especially as the updated data encompasses over three years of follow-up. This comprehensive analysis has shown longstanding progression-free survival (PFS) and time to next treatment intervention (TTNI), reaffirming VORANIGO's sustained treatment benefits.

Moreover, findings from an exploratory analysis within the INDIGO trial will also be shared, illustrating how prolonged treatment with VORANIGO can reduce the frequency and severity of seizures while enhancing patients' quality of life.

Highlighting Emi-Le

In addition, Day One Biopharmaceuticals, now part of Servier Group, plans to share exciting data from an ongoing Phase 1 trial evaluating the investigational compound Emi-Le (emiltatug ledadotin) for treating adenoid cystic carcinoma (ACC). This targeted presentation, slated for June 1 at 8:24 a.m. CDT, aims to reveal the promising tolerability and potential anti-tumor efficacy of Emi-Le in patients with advanced ACC, who have limited treatment options and typically poor prognoses. The ongoing clinical development of this compound is expected to offer fresh hope in the field of targeted cancer therapies.

A Broader Commitment to Oncology

Servier's commitment to expanding its oncology portfolio is underscored by its plan to also present findings from a placebo-controlled trial of vorasidenib in newly diagnosed Grade 3 astrocytoma, conducted in collaboration with the Alliance for Clinical Trials in Oncology.

Becky Martin, PhD, Chief of Medical at Servier Pharmaceuticals, articulated the company’s dedication to transformative medical solutions for patients with significant unmet needs, stating, "These presentations highlight the evolution of our oncology portfolio and showcase our readiness to tackle rare cancers with innovative therapies."

Servier will additionally present updates on their research at the European Hematology Association (EHA) 2026 Congress from June 11-14 in Stockholm, further solidifying their role as a pivotal player in the field of oncology.

About Servier: Committed to Therapeutic Progress

Servier is an independent international pharmaceutical group governed by a foundation, ensuring a long-term commitment to therapeutic advancements that serve patients. With a strong focus on rare cancers and neurological diseases, the company invests about 20% of its brand-name sales in research and development annually. Servier’s workforce of over 20,000 employees supports its presence in over 130 countries. The company aims to lead in innovative oncology solutions that cater specifically to rare diseases, reinforcing its impact on improving patient lives throughout the world.

For more details and to stay updated on Servier’s ongoing research, visit their official website at Servier.com.